Table 4.
Characteristics of patients with nevi
| Code LB | Sex | Age (Y) | Location | ctDNA | FA | B | TN | FU | RX | RF | Notes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 06 | F | 73 | Choroid | 0 | 0 | 3 | Flat | 81 | – | 0 | – |
| 07 | M | 72 | Choroid | 0 | 0 | NA | Flat | 53 | – | 0 | – |
| 08 | M | 80 | Choroid | 0 | 0 | 2 | Flat | 141 | – | 0 | – |
| 09 | M | 79 | Choroid | 0 | 0 | 1.5 | 1.3 | 170 | – | 0 | – |
| 10 | M | 83 | Choroid | 0 | 0 | 3 | Flat | 182 | – | 0 | Bilateral |
| 11 | M | 64 | Choroid | 0 | 0 | 4 | Flat | 48 | – | 0 | – |
| 12 | F | 70 | Iris | 0 | 0 | 2.4 | 0.6 | 170 | – | 0 | – |
| 20 | M | 77 | Choroid | 3.1 | 1.1 | 1.8 | NA | 11 | + | 4 | OP, S, F, PP |
| 23 | F | 57 | Choroid | 12.1 | 1.8 | NA | NA | 5 | + | 4 | T, OP, F, S |
| 24 | F | 68 | Choroid | 4.3 | 0.7 | NA | 2.3 | 15 | – | 3 | PP, F, T |
| 25 | F | 35 | Choroid | 13.3 | 28 | 4.5 | 2.47 | 13 | + | 4 | F, S, T, G |
| 34 | M | 80 | Choroid | 2.3 | 0.6 | NA | NA | 9 | – | 2 | OP, F |
| 35 | F | 60 | Choroid | 0 | 0 | 2 | Flat | 12 | – | 0 | – |
| 37 | F | 47 | Choroid | 1 | 7 | 7 |
OD: Flat. OS: 1 |
82 | – | 0 | Bilateral |
| 38 | F | 45 | Choroid | 2.3 | 6 | 3.2 | 1.7 | 12 | – | 4 | OP, F, PP, S |
| 45 | F | 60 | Choroid | 4.4 | 1.8 | NA | 2.7 | 18 | – | 2 | PP, T |
+ = anti-VEGF treatment; B Basal diameter (mm); ctDNA (molecules/ml). F fluid; FA percentage of fractional abundance; FU follow-up time (months); G Growth; OP orange pigment; PP peripapillary; RF number of risk factors; Rx Treatment; S visual symptoms; T thickness > 2 mm; TN thickness (mm);